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5-HD

5-hydroxydecanoate

cGMP

Cyclic guanosine monophosphate

HR

Heart rate

LAD

Left anterior descending coronary artery

L-NAME

N,-Nitro-L-arginine methyl ester hydrochloride

MAP

Mean arterial pressure

NO

Nitric oxide

NOS
eNOS
iNOS
nNOS

Nitric oxide synthase
endothelial nitric oxide synthase
inducible nitric oxide synthase
neuronal nitric oxide synthase

PC

Preconditioning

PDE-5

Phosphodiesterase-5

PKG

Protein kinase G

RPP

Rate-pressure product

RTPCR

Reverse transcriptase polymerase chain reaction

Sil

Sildenafil

TTC

2,3,5-triphenyltetrazolium chloride

Var

Vardenafil
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LONG-TERM CARDIOPROTECTION WITH PHOSPHODIESTERASE-5 INHIBITION
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Recent studies have shown that the potent phosphodiesterase-5 (PDE-5) inhibitor,
sildenafil citrate, induces a powerful cardioprotective effect against ischemia-reperfusion
(IIR) injury in rabbit and mouse hearts. However, the effect of this drug in inducing longterm protection against VR injury remains unknown. The goal of this study was to identify
the duration of the protective window of sildenafil citrate as well as vardenafil, a more
potent PDE-5 inhibitor. Rabbits were treated with sildenafil (0.7 mg/kg, iv), vardenafil
(0.143 mglkg), or an equivalent volume of saline. After 24 hrs, 48 hrs, 96 hrs, or 7 days of
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sildenafil treatment, the hearts were subjected to I/R. In the vardenafil groups, the hearts
were subjected to I/R at 24 hrs and 7 days after administration of the drug. To evaluate the
role of nitric oxide (NO) in cardioprotection, a non-selective blocker of nitric oxide
synthase, L-NAME (15 mgkg, iv) was administered 10 minutes prior to IIR. The results
show significant reductions in infarct size in hearts treated with sildenafil and vardenafil as
compared to the corresponding saline controls at all time points. The protective effects of
sildenafil and vardenafil were abrogated in animals treated with L-NAME. L-NAME had
no effect on infarct size in saline treated control rabbits. These data suggest that both
sildenafil and vardenafil induce a long-term protective effect against myocardial infarction
which is mediated via a NO-dependent pathway. These studies are important in exploiting
the

clinical

potential

of

PDE-5

inhibitors

in

terms

of

ischemia~reperfbsioninjury in patients with coronary artery disease.

protection

against

INTRODUCTION

Restoration of blood flow (reperfusion) to a previously ischemic organ or tissue is a
necessary step in the recovery process; however, there is a caveat. Reperfusion can further
propagate an injury and ultimately result in myocardial cell death. A reduction in the
amount of viable myocardium leads to an inevitable decrease in the ability of the heart to
perform its primary function: the pumping of blood to both the systemic and pulmonary
circuits. Clearly, preserving any myocardial tissue after an ischemic insult is beneficial in
the clinical realm. Such implications could have profound effects on the lives of many
individuals who suffer from the various cardiovascular problems in our present time.
Ischemic preconditioning is a cardioprotective mechanism against myocardial-cell
death and cardiac dysfunction that results from the reperfusion of an ischemic heart (29).
Murry et a1 used brief periods of ischemia to evaluate a potential preconditioning effect in
the canine heart (26). These authors demonstrated that a brief episode of ischemia slowed
the rate of ATP depletion that occurs during subsequent ischemic episodes. It was also
shown that periods of intermittent reperfusion may be beneficial to the myocardium in that
they washed out catabolites that tend to accumulate during an ischemic event. They found
that ischemic preconditioning resulted in a significant reduction of infarct size within the
at-risk area of the canine heart by an average of 25% when compared to controls (26).

Studies in both the rabbit and the canine heart have demonstrated that the
cardioprotective effect of ischemic preconditioning appears in two phases: an acute or
classical phase which is detectable within minutes after bI;ief episode(s) of ischemia and
reperfusion and the delayed phase, which appears 24 hours following the initial ischemic
insult and has been shown to last up to 96 hrs (2 1, 24). Classical forms of preconditioning
have limited significance in the clinical realm due to the narrow time window within which
the myocardium is actually protected.

However, delayed preconditioning is relevant

clinically in that it follows approximately 24 hours after the insult and tends to last much
longer than classical preconditioning.

The delayed phase of preconditioning can be

produced not only via sub-lethal ischemia, but also by heat shock (10) and various other
endogenously released triggers such as adenosine (3), norepinephrine (2), bradykinin (20),
oxygen radicals (7) and opioids (35).

It has been widely accepted that the delayed

cardioprotective window induced by said pharmacological agents is mediated by an
increase in NO production (4, 45). Moreover, NO may modulate KATp-channelsensitivity
to intracellular ATP (38).

Several studies have shown the importance of mitochondrial

KATPchannels in cardioprotection (8). Using diazoxide, a mitochondrial KATPchannel
opener, Garlid et a1 were able to produce significant cardioprotective effects in an isolated,
perhsed heart (14). Furthermore, Liu et a1 found a substantial reduction in the rate of cell
death following simulated ischemia in adult ventricular myocytes (23). The protection
provided by the mitochondrial KATPchannels was confirmed when the cardioprotective
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effects were abolished upon the addition of 5-hydroxydecanoate (5-HD), a selective
mitochondria1 KATPchannel blocker (23).
It is clear from the brief review above that extensive research and publications in
the field of ischemic preconditioning have vastly extenged our understanding of the
mechanisms underlying the pathogenesis of I/R injury. There can be little doubt that the
elucidation of the pathophysiology and cellular mechanisms of the phenomenon of
ischemic preconditioning have enabled us to learn a means of protecting the myocardium
in the experimental setting. This evolving field, however, has so far failed to provide any
direct evidence that this plethora of experimental and clinical research may one day
translate into a clinical reality that would ultimately benefit patients with coronary artery
disease. Despite this, the knowledge gained as a result of this research has provided us
with tools for protecting myocytes and has enabled us to identify several classes of
pharmacological agents that may be able to mimic the protection conferred by ischemic
preconditioning.

These include agents aimed at triggering the preconditioning

phenomenon such as adenosine or its more selective analogues, bradykininlangiotensinconverting enzyme inhibitors and opioids, and those that target the putative distal mediator
of preconditioning (mito-KATPchannels), such as nicorandil.
In the quest for novel drugs in preconditioning, Dr. Kukreja and colleagues used
phosphodiesterase-5 (PDE-5) enzyme inhibitors for cardioprotection. PDE-5 inhibitors are
the class of drugs used for the treatment of erectile dysfunction (ED) in men. Sildenafil
citrate (viagram)is one such drug approved for ED (5, 18). It has a proven record of safety
in humans as predicted by the results of extensive pharmacological and toxicological

4

testing in animals and in vitro. This has been confirmed by pharmacokinetic exposure data
as well (1). Sildenafil selectively inhibits PDE-5, the enzyme that catalyzes the breakdown
of cyclic-GMP, a potent, endogenous, smooth muscle relaxant.

Sildenafil acts by

competing with cGMP for the active site on PDE-5 (9). Stydies have shown that sildenafil
also serves to enhance nitric oxide (NO)-driven cGMP accumulation in the corpus
cavernosum of rabbits without affecting the formation of cyclic-AMP. In the absence of a
NO drive, sildenafil potentiated the relaxing effects of NO in the isolated corpus
cavernosum, but had no functional effect on said tissues isolated from both the human and
the rabbit (32). Many of the biological actions of NO occur via the activation of soluble
guanylyl cyclase (GC) and the resulting increase in cGMP tissue levels. Moreover, cGMP
has been shown to exert a number of actions that would be expected to be beneficial during
myocardial ischemia (44, 22, and 37). According to studies by Kodani et al, the increased
synthesis of cGMP is necessary in order to produce cardioprotection in delayed ischemic
PC in the rabbit heart (19).
Vardenafil is the active ingredient in another PDE-5 inhibiting drug for ED called
~ e v i t r a ~Like
. sildenafil, vardenafil binds to the active site on the PDE-5 enzyme, thereby
inhibiting the binding of cGMP and thus preventing the breakdown of cGMP (9). For
cardioprotection studies, it was hypothesized that the mild vasodilatory effect of sildenafil
could potentially release agents such as adenosine, bradykinin, or nitric oxide, which may
in turn trigger a preconditioning-like effect in the myocardium (28). Studies have shown
that, in the rabbit heart, sildenafil induced both acute and delayed cardioprotective effects,
both of which were occurring through a pathway dependent on the opening of
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mitochondrial KATPchannels (28). Salloum et a1 have further demonstrated that sildenafil
causes an increase in endothelial (eNOS) and inducible NO synthase (iNOS) in the mouse
heart and that the magnitude of increase was more pronounced for iNOS than for eNOS
(32). A direct protective effect of sildenafil was also shown against necrosis and apoptosis
in cardiomyocytes through a NO-signaling pathway (1 1). Furthermore, Das et a1 found
that sildenafil enhanced mRNA and protein content of both iNOS and eNOS. In the same
study, myocytes treated with sildenafil prior to simulated ischemia and reoxygenation
showed a significant increase in the anti-apoptotic protein, Bcl-2.

The increased

expression of Bcl-2 was inhibited by L-NAME, an inhibitor of nitric-oxide synthases. It
was also suggested that sildenafil may trigger a signaling cascade that involves the
generation of NO and the accumulation of cGMP in the myocytes through an eNOS- and
iNOS-dependent pathway. This would therefore lead to the opening of the mitochondrial

KATPchannels and thus allow for the observed cardioprotective effects (1 1).
Goals of the Study
Although previous studies from our laboratory have shown the protective effect of
sildenafil against IIR injury up to 24 hrs after treatment, it is unclear whether sildenafil or
vardenafil have a long lasting protective effect extending beyond the 24-hour period. The
current study was designed to identify the window of cardioprotection induced by these
drugs in vivo. Since NO was observed to be an essential component of delayed protection
at 24 hrs with sildenafil (32), we were interested in further identifying the role of NO in
long-term protection with PDE-5 inhibitors. Accordingly, we addressed the following two
questions in the present study:
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1.

To determine the time course of the cardioprotective effect of sildenafil
and vardenafil in the rabbit model of ischemiah-eperfusion injury.

2.

To show the role of NO in inducing a cardioprotective effect during
long-term protection with sildenafil and vqrdenafil.

Our results show that both drugs reduced infarct size following I/R injury, which
was observed up to 7 days and possibly even longer after the treatment. Moreover, the
non-selective nitric oxide synthase inhibitor, L-NAME (N,-Nitro-L-arginine methyl ester
hydrochloride), blocked the protective effect, thus confirming the role of a NO-dependent
pathway.

MATERIALS AND METHODS

Animals
Male New Zealand White rabbits, obtained from Blue and Gray Rabbitry
(Unionville Lane, Virginia), were used in this study. The rabbits were weighed (2.5 kg to
3.5 kg) and the values were recorded directly on the animals' ear for proper identification.
The care and use of the animals were conducted in accordance with the guidelines of the
Institutional Animal Care and Use Committee of Virginia Commonwealth University and
the National Institutes of Health (NIH) Guides for Care and Use of Laboratory Animals
[DHHS Publication No. (NIH) 80-23; Office of Science and Health Reports, Bethesda,
MD 202051. Each group was comprised of 6 animals.
Drug Preparation and Administration
Sildenafil citrate (viagraB) tablets were crushed and ground to a fine powder using
a ceramic mortar and pestle. The compound was then weighed and dissolved in 3 cc of
sterile 0.9% saline solution (0.7 m g k g sildenafil citrate). The drug was administered
intravenously through left or right ear via the marginal vein.

Depending on the

experimental group, the rabbits were allowed to remain for 24, 48, 96, or 168 hours (7
days) prior to undergoing the surgery protocol as described below. L-NAME (15 mgkg)
was given to the appropriate groups intravenously 10 minutes before ischemia. A pure
compound of vardenafil HC1 was weighed, with 1 mg of the compound being dissolved in
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7 ml of 0.9% saline. Each animal received 0.143 m g k g of vardenafil. The drug was given
intravenously through the marginal vein in the ear.
Surgical Procedure
The rabbits were given a 1.5 cc injection (intramuscularly) that contained ketamine
HCl(35 mgkg), xylazine (5 mglkg), and atropine. The atropine was administered in order
to sustain an elevated heart rate throughout the entire surgical protocol. Subsequent doses
of anesthetic were given at 40 minute intervals in order to maintain appropriate levels of
surgical anesthesia.
A ventral midline incision was made in the neck. A tracheotomy was performed,
followed by intubation of the animal. The animals were ventilated mechanically with a
positive-pressure ventilator and oxygen was administered via the ventilator as well. The
left carotid artery was dissected and cannulated with a polyethylene (PE) catheter and
filled with saline and heparin for continuous arterial pressure and hemodynamic
monitoring. The right jugular vein was also cannulated with a PE catheter containing
saline with heparin for continuous infusion of 0.9% saline solution.

In some cases,

electrocardiographic leads were attached to subcutaneous electrodes in order to monitor
either limb lead I1 or lead 111. Baseline values for systolic and diastolic blood pressure
were recorded, as well as values for mean arterial pressure and heart rate.
After hemodynamic stabilization was achieved, a left thoracotomy was performed
via the fourth intercostal space. The pericardium was then opened in order to gain access
to the heart. Hemodynamic data were recorded again after the thoracotomy and just prior
to the induction of ischemia. A 5-0 silk suture equipped with an atraumatic needle was
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used to circumvent the left anterior descending (LAD) coronary artery at the halfway point
between the atrio-ventricular groove and the apex of the heart. The needle was cut from
the suture and the two ends were passed through a vinyl tube that had previously been
heated and slightly melted so as to not cause damage to the, myocardial tissue and to form
an effective snare. The smooth end of the snare was pressed securely against the heart and
fixed in place with a hemostat in order to occlude the vessel (Figure 1). Ischemia in the
myocardium was confirmed either by direct visualization of the tissue in situ due to the
presence of regional cyanosis, ST elevation and subsequent depression on the
electrocardiogram, or T wave inversion on the electrocardiogram. After 30 minutes of
ischemia, blood pressure and heart rate values were recorded, and the snare was released.
The suture remained in place although it was no longer preventing blood flow within the
LAD. The area was gently massaged with a cotton-tipped applicator to promote regional
blood flow. Reperfusion of the heart was allowed to occur for 180 minutes. Reperfusion
was confirmed by hyperemia in the regions of the myocardium that were previously
cyanotic. Pressure and heart rate measurements were taken every 60 minutes during the
reperfusion phase of the protocol. To prevent desiccation, the thoracic cavity was covered
with a piece of saline-soaked gauze.
Upon completion of the VR protocol, the heart was removed and mounted on a
Langendorff apparatus. The coronary arteries were perfused with a 0.9% saline solution
containing 2.5 mM CaC12in order to wash out any blood that remained. The suture around
the LAD was tied off completely and about 2 ml of 10% Evan's blue dye were injected
into the aorta until most of the heart turned blue. The excess Evan's blue dye was washed
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away by perfusing the heart with more saline. The heart was then removed from the
Langendorff apparatus, placed into a Petri dish, and moved to a freezer for approximately
24 hours to facilitate the next step in the protocol. The frozen heart was then cut into
approximately 6 transverse slices of equal thickness, startiqg from the apex and ending at
the base. The slices were then incubated in 1% 2,3,5-triphenyltetrazolium chloride (TTC)
solution of isotonic pH 7.4 phosphate buffer at 37OC for 20 minutes. The TTC reacts with
NADH in the presence of dehydrogenase enzymes, causing the viable cells to stain with a
deep red color and the dead myocardial tissue to remain pale in color. This allowed for
easy differentiation between viable tissue and infracted gray or white necrotic tissue.
Following the staining with TTC, the slices were fixed with a 10% formalin solution. The
at-risk area was determined using negative staining with the Evan's blue dye. The portions
of tissue that were not at risk from coronary occlusion stained a deep blue color while the
at-risk regions did not. Computer morphometry (Bioquant imaging software - BI098) was
used to measure the area of infracted tissue, the risk zone, and the whole left ventricle.
Infarct size has been expressed as a percentage of the ischemic risk area.

Statistical Analysis
All measurements of infarct size and risk areas are expressed as group means

*

SEM. Changes in hemodynamics and infarct size variables were analyzed by two-way
repeated-measures ANOVA to determine the main effect of time, group, and time-bygroup interaction. If the global tests showed major interactions, post hoc contrasts between
different time points within the same group or between different groups were performed
using a t-test. Statistical differences were considered significant if the P value was <0.05.

Figure 1. Snare placement and infarction. After the left thoracotomy was performed,
the LAD was identified and a 5-0 silk suture passed around it. The two ends of the thread
were passed through the tubing and the snare was fixed in place via a hemostat.
Confirmation of successful occlusion was achieved by noting regional cyanosis, as seen in
this photograph.

RESULTS

Risk Area and Infarct Size
The risk areas for all of the hearts were similar in size, ranging from 46.20%

+ 3.48

to 58.05% f 6.78 (Figures 2, 4 and 6). These data suggest that changes in the infarct size
observed among various groups were not related to the percentage of the area of the left
ventricle that was occluded by our technique. In figure 3, it is clear that the group with the
smallest infarct size (% of risk area) was the one receiving sildenafil from 48-168 hrs prior
to VR. Overall, it can easily be seen that the groups receiving sildenafil, regardless of the
time interval, had much smaller infarcts when compared to the control groups (Figure 3).
As seen in figure 5, the addition of L-NAME abolished the protection conferred by
sildenafil. The animals receiving sildenafil 24 hrs prior to VR had an average infarct size
of 19.77% f 1.46, which was increased to 30.77%

+ 1.83 in L-NAME treated rabbits.

Such increase in the infarct size in sildenafil + L-NAME treated animals was not different
when compared with saline treated controls (35.89%

+ 1.54).

Similarly, the group of

+

animals receiving sildenafil 168 hrs prior to I/R had an infarct size of 16.37% 1.94 which
increased to 3 1.61% f 1.22 following treatment with L-NAME.

Again this increase in

infarct size was not significantly different as compared to the

saline treated control

animals, which had an average infarct size of 37.28%

+ 1.39 (Figure 5).

L-NAME alone
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had an infarct size of 34.9 % f 0.91, which was not significantly different when compared
to the saline treated control groups 35.89 % f 1.54 (24 hrs) or 37.28 % f 1.39 (168 hrs)
subjected to ischemia/reperhsion protocol.
In figure 7, the groups receiving vardenafil showed, significant protection at 24 hr
and 168 hr (7 days) time intervals. The infarct size was 18.31 f 1.73 and 22.09 f 1.12 in
the vardenafil-treated rabbits, which was significantly lower as compared to the infarct
sizes of 33.4% f 1.03 and 34.8% k 1.61 in the saline treated controls at 24 and 169 hrs
respectively. Similar to sildenafil, treatment with L-NAME abolished the ~ardio~rotective
effect of vardenafil. The infarct size increased to 32.31% f 2.24 at 24 hrs and 31.24% f
1.51 at 168 hrs following treatment with L-NAME. The infarct sizes in vardenafil

+ L-

NAME treated groups were comparable to the saline-treated controls: 33.4% f 1.03 and
34.8% f 1.61 at 24 and 168 hrs after treatment, respectively (Figure 7).

Hemodynamic Findings
The changes in hemodynamics immediately following treatment with sildenafil and
vardenafil have been reported previously from the laboratory (28, 31).

Intravenous

administration of sildenafil citrate induced a rapid decrease in the hemodynamics as
demonstrated by the 24.5%, 47.3%, and 38.8% decline in systolic, diastolic, and mean
arterial pressures, respectively, within 2 min. The systemic hemodynamics bounced back
to nearly baseline levels within 5 min after treatment with sildenafil. No significant
changes in heart rate were observed. Similarly, after treatment with vardenafil, the mean
arterial blood pressure decreased from 93.5 h 2.6 to 82.2

1.5 mm Hg and heart rate
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(beatslminute) increased from a baseline value of 151

* 20 to 196 * 4.6 (mean * SEM,

p<0.05) within 5 minutes of drug administration.
During IIR, the heart rate, MAP and RPP are shown in Table 1 (for sildenafil and
controls), Table 2 (for sildenafil + L-NAME) and Table 3 (for vardenafil and vardenafil

+

L-NAME). There was no significant difference in the baseline levels of these parameters
between the different groups.

Moreover, the heart rate, MAP and RPP remained

reasonably stable throughout the reperfusion period, though there was a gradual decrease
in all of the groups during this time. Except at the indicated time points, the mean values
were not significantly different between the groups at any time point.

Significant

decreases in heart rate were observed in the groups treated with L-NAME. Also, the ratepressure product was found to be significantly lower in the L-NAME treated groups as
compared to the other groups during IIR.

USildenafil 24hrs
Control 24hrs
Sildenafil48hr.s
Control 48hrs
ESildenafil 96hrs
Control 96hrs
Sildenafil 168hrs
E Z i Control 168hrs

Figure 2. Risk area for long-term sildenafil treatments and controls. The risk area of
the left ventricle was determined using Evan's blue dye.

0 Sildenafil 24hrs
Control 24hrs
I
Sildenafil 48hrs
Control 48hrs
ESildenafil 96hrs
Control 96hrs
Sildenafil 168hrs
tZA Control 168hrs

Figure 3. Infarct size of long-term sildenafil treatments and controls. TTC staining
was used to assess the amount of viable tissue remaining in the myocardium. Infarct size
is expressed as a percentage of the at-risk tissue that suffered from infarction. Control
groups received saline only.

0Sildenafil 24hrs
Control 24hrs
Sil + LNAME 24hrs
Sildenafil 168hrs
EControl 168hrs
Sil + LNAME 168hrs

Figure 4. Risk area for sildenafil treatments and L-NAME. The L-NAME, a NOsynthase inhibitor, was given 10 minutes prior to ischemia. Evan's blue dye was used to
determine the at-risk area of the left ventricle.

0 Sildenafil 24hrs

Control 24hrs
Sil + LNAME 24hrs
Sildenafil 168hrs
EControl 168hrs
Sil + LNAME 168hrs

Figure 5. Infarct size of sildenafil treatments and L-NAME. L-NAME was given 10
minutes prior to ischemia-reperfusion. TTC staining was used to assess the amount of
viable tissue present within the risk area.

Table 2: Hemodynamic data for sildenafil groups and saline controls

I Pre-Ischemia

I Baseline

Group

Sil24 hrs (Group I)
HR
MAP
RPP
Saline Control 24 hrs (GrouplI)
HR
MAP
RPP
Sil48 hrs (Group 111)
HR
MAP
RPP
Saline Control 48 hrs (Group IV)
HR
MAP
RPP
Sil96 hrs (Group V)
HR
MAP
RPP
Saline Control 96 hrs (Group VI)
HR
MAP
RPP
Sil7 days (Group VII)
HR
MAP
RPP
Saline Control 7 days (Group VIII)
HR
MAP
RPP

*

182f 15
84f2
17709f2217

I 30-min Ischemia 1

60-min

1 Reperfusion

(

143f 10'
169 f 6
66 f 3eqf
64 f 3e-f
12937 f 8 ~ 7 ~ * ' 10575 f 732"'

190f 14
80 f 2"
17248f 1708

126 f 1 2 ~ ~ '
66 f se3'
9 110 f 976",'

1 8 2 f 13
187f 9
177f 12
191 f 14
80 f 3bs.e
79 f 3 " ~ " ~
100 f 7"
96 f 6'
6545
10482 f 1762a3b.c 967 1 f 11 2 8 % ~ ~
~ f 495a3c3de 6669 + 469"C.de

1

1

177f 11
85f5
15528f1500

1
(

189f 8
83f2
16852k2046

1

1

187f 7
72f4
15821f1425

1

1

185f 13
2 0 6 f 12
205 f 11
83 f 4a,b-c
95 f 5"'
98 f 8"
10260 f 1872a.b-c 9503 f 1 0 1 5 " ~ ~ ~7 161 f 752a.C3d

1

163f 18
85f3
16566f2253

(

186f9
77f 3
16759f1345

181 f 7
97f 4
9680 f 722a,b.c

187f 9
94 f 4a"
9222 f 863a.b,d

198f 15
75f 5
17180f1043

201 f 14
74 f 5
17265f1038

199f 13
94f 5
9458 f 922aqb-c

201 f 7
93f 4
9054 f 687"b.d

(

195f 7
59 f 4e-f
14122f1109

1

158f 11
69f5"
13345f1952

1

1

1

188f8
181 f 9
78 f 2e3f
75 f Fe.'
6342 f 364a9c.4e.f 5868 f 378"c9de.f
197f8
65 f 3
15905 f 1132

135 f 13~.'
61 f se.'
9639 f I O O ~ ~ . '

168f 13
164f 15
75 f 3".'
70 f 6e9f
591 8 f 526"C.de-f 5208 f 736ac.4e.f

193f1l"~ (
78 f 4'
6380 f 660%"~
168f 10
55 f 3e2f
11464f1042

I Reperfusion

Reperfusion

148 f
69+4
12044 f 858e3f9g

l 5 8 f 14
6~+4~.'
12859f2121

1

1

190f12~
73 f 5".'
5678 f 823a.c34e
159 f 14
59 f 6".'
11628f1603

15Of 15
62f4e9f
11178f1864
190f 1 2 ~
71 f 6e*f
5217 f 8 1 6 " ~ ~ ~ ~

(

154 f 14
58 6e.f
11040f1535

+

-

174f 11
170f 13
71 f 2".'
64 f 4e3f
5277 + 2 1 2 " ~ ~ ~ ~
" f4 0 9 ~ ~ . ~ " . '
4362
145 f 8e,f*g
69 f 2
115 13 f 647e,f,g

141 f 6e3f3g
66f 3
10773 f 807"~'~~

193 f 6ab
196 f 7
196 f 6"b
196f 7"b
82 f 4a.b,C
73 f 3e.f
69 f 4e.f
64 f 4e.f
6959 f 709a9c.de.f 5579 f 5 16a.c3de.f 5037 f 6194C-de3f 4365 f 542ac9de9f

Values are means SEM. HR - Heart rate (beatdmin); MAP - Mean arterial blood pressure (mmHg); RPP - Rate pressure product (mmHg/min),
"P<O.05vs Sil7 days, b ~ < ~ .vs0 Sil24hrs,
5
'P<O.05 vs Sil96hrs, d ~ < ~ .vs0 Sil48hrs,
5
'P<O.05 vs baseline,'p<0.05 vspre-ischemia, g ~ < 0 3 vi
5 30
min ischemia.

Table 3: Hemodynamic data for sildenafil, sildenafil + L-NAME and controls
Baseline

Group

Sil24 hrs (Group I)
HR
MAP
WP
Saline Control 24 hrs (Group 11)
HR
MAP
RPP
Sil24 hrs + L-NAME (Group 111)
HR
MAP
RPP
Sil 7 days (Group IV)
HR
MAP
RPP
Saline Control 7 days (Group V)
HK
MAP
RPP
Sil7 days + L-NAME (Group VI)
HR
MAP
RPP
L-NAME Control (Group VII)
HK
MAP
RPP

*

Pre-Ischemia

30-min Ischemia

60-min
Reperfusion

120-min
Reperfusion

180-min
Reperfusion

182f 15
84f 2
17709f2217

190f 14
80 f 2
17248f1708

169f 6
66 3d.e
12937+887d.e

+

143 10"
64 3d,e
10575 732'"

+
+
+

126 f 12d,e
66 f sd,"
91 10f 976d,"

135 f 13d.e
61 +5d,e
9639 f 1 0 0 3 ~ ~

187f9
100f 7
10482f1762"

191 f 14
96f6
9671f1128"

l 7 7 + 12
79 f 3a.d
6545 f 49sd

182+ 13
8 0 f 3ad
6669 f469d

168f 13
75 f 3d,e
59 18 526d,e

+

164 f 15
70 f 6d.e
5208 f 736d.e

169f 20'
84 8
15938 f 1138

144f 16
107+ 14
15488 +2421

135 I lb,'
84 f 5"
13124f 1376"'

128f 10'
79f 3
1 1271 f 700b.'

119f 9'
76 3
10015 524b.c,d

+

198 f 15
75 5b
17180 f 1043~.'

+

+

+
+

145 f 8C,d,e,f
14 1 + 6c,d.e3f
148 f I o'.'",~
197f 8
201 f 14
69+4
65 f 3b.C
74+5
69+2
66+3
17265 f 1038~~' 15905 f 1 1 3 2 ~ ~ ' 12044 858b.c.4e.f 1 1513 f 647b3'.d".f 10773 807~,','",~

+

+

199+ 13
94+5
9458 f 922"

201 7
93 + 4
9054 f 687"

196f 7
82 f 4"
6959 f 709~,"

182f 13
84+4
17508 f 1453~.'

158f 1 1
91 f 3
17188 f 1 264b.'

145 1
82 f 4"
14022 1126"',~,"

+
+

191 f 9
101 f 23
17426 f 805"'

182 8
85f 6
17837 920b.'

+

130 8b.C
87 f 3".'
12474 f 907~,'

+
+

177f 13
75f 3
14346 f 103Sb.'

193 f 6"
73 f 3d,e
5579 516d.e

+
129 + 8b.c.d

+

196+6"
69 f 4'"
5037 f 619d.e

196f 7ab
64 + 4d.e.f
4365 542d,"

+

+

129
118 f 8',d
86 f 3a.d
77 f 6
74+7
12390 f 690~.'.~" 1 1859 f 506~,'.~" 9802 f 293b,c,de,f
160f 19
155 f 20'
138f 15'
70+ 1
692 1
68f 1
12609 f 1 1 84b,c,d.e 12286 f 1397b.c.d.e 10761 f 999b.c.de

Values are means SEM. HR - Heart rate (beatdmin); MAP - Mean arterial blood pressure (mmHg); RPP - Rate pressure product (mmHg/min).
"P<0.05 vs Sil24hrs, b ~ < 0 . 0 vs
5 saline 24hrs, 'P<0.05 vs saline 7 days, d ~ < 0 . 0 5vs baseline, 'P<0.05 vs pre-ischemia, f ~ < 0 . 0 5vs 30min ischemia.

Table 4: Hemodynamic data for vardenafil, vardenafil + L-NAME and controls
Gram

I Baseline

I Pre-Ischemia

1

Vardenafil24 hrs (Group I)
190f 14
HR
182f 15
MAP
80f 2
84 f 3
RPP
17248f1708
17709f2217
Saline Control 24 hrs (Group 11)
1912 14
187f 9
HR
MAP
96f 6
100f7
RPP
10482 f 1762"
9671 1 128
Vardenafil24 hrs + L-NAME (Group 111)
193f 8
180f 17
HR
MAP
107f 10
83f 8
RPP
1881 1 32 1 8b.d 2394 1 f 3 137ab.c.d
Vardenafil7 days (Group IV)
201 f 14
198 f 15
HR
MAP
74f5
75f5
RPP
17265 f 1 0 3 8 ~
17180 f 1044
Saline Control 7 days (Group V)
201 f 7
199f 13
HR
MAP
93f4
94f5
RPP
9458 f 922"
9054 f 687'
Vardenafil7 days + L-NAME (Group VI)
171 f 11
189f8
HR
MAP
104f 7
87 + 13
RPP
19593 f 1 4 8 8 ~ ~ ' 19712 f 11Bb,'
L-NAME Control (Group VII)
182f 8
191 f 9
HR
MAP
101 f 23
85f 6
RPP
f 805"~
17837 f 9 2 0 ~ ~ 17426
~

1

1

+

1

+

1

I

1

1

1

30-min Ischemia

60-min

I Reperfusion

I Reperfusion

(

Reperfusion

169f 6
66 f 3e.f
12937 f 887

143 f 10'
64 f 3e-f
10575 f 732e-f

126f 12e-f
67 f 5e.f
9 110 f 976e,f

135 f 13".~
6 1 f se.'
9639 f 1 003~,'

177f 12
79 3e
6545 f 495a3e

1

182 f 13
80 f 3'
6669 f 469".'

168+ 13
75 3e,f
5918 f 526",",'

164f 15
70 f 6".'
5208 f 736ae.f

1495 18
86 f 8".'
14105 f 11 84b.d.f

145 + 18
6 6 f 10'
10263 f 663','

+

1

+

145 f lod
52 f 8b.f
8674 f 852".'

134f l l d
55 f 10'
83 1 1 f 1054".~

I

197f 8
65 f 3
15905 f 1 1 3 2 ~

148 f
145 f 8e,f
69f 4
69+2
12044 8 ~ 8 ~ ~11513
~ ~f '647b,e,f

196f 7
82f 4
6959 f 709".'

193 f 6esf
73f3
5579 f 5 16a-',e.f

131 f 13C-e-f
82f6
1 1805 f 993'3e9f

(

141 f 6e,f
66f 3
10773 f 807b-esf

+

1

1 96 + 7ac.e-f
196 f 6a'-esf 1
69f 4
64 f 4
5037 f 6 19a.c-e-f 4365 f 542a.c,e,f

I

121 f 9b.d3e3f
82 f 1
11200 f 908b-d.e,f

117 f I O ~ - ~.- ' I 11l f 12b,d,e.f
74 f 5
72f 7
9792 f 656b.d.e3f 8748 f 3 1 9b.d-e-f

177 f 13
160f 19
155 f 20
138 + lsd
70f 1
75 f 3
69f 1
68f1
14346 f 1 0 3 5 ~( ~12609
~
f I I 84bdef 12286 f 1397b-d3e*f10761 f 999b-dse.f

1

1

Values are means 7t SEM. HR - Heart rate (beats/min); MAP - Mean arterial blood pressure (mmHg); RPP - Rate pressure product (mmHg/min).
'P<O.05 vs Var24hrs, b ~ < ~ . vs
0 5saline 24hrs, 'P<O.05 vs Var 7 days, d ~ < ~ . vs
0 5saline 7days, eP<0.05 vs baseline, f ~ < ~ . vspre-ischemia.
05

DISCUSSION

Ischemic heart disease, as the underlying cause of most cases of acute myocardial
infarction (AMI), congestive heart failure, arrhythmias, and sudden cardiac death, is the
leading cause of morbidity and mortality in all industrialized nations. In the United States,
ischemic heart disease causes nearly 20% of all deaths (approximately 600,000 deaths each
year), with greater than half of these deaths occurring before the patient arrives at the
hospital, primarily due to arrhythmias and cardiac arrest.

An estimated 1.1 million

Americans will have a new or recurrent AM1 this year, and many survivors will experience
lasting morbidity, with progression to heart failure and death. As the population grows
older and co-morbidities such as obesity and diabetes become more prevalent, the
enormous public health burden caused by ischemic heart disease is likely to increase even
more. Two critical factors are required in order to improve the outcome of a patient
suffering fiom an acute, ischemic event. First, the patient must survive any arrhythmias.
The majority of deaths due to AM1 occur prior to hospitalization, due primarily to
arrhythmias and cardiac arrest. Although greater access to automatic defibrillators and
optimization of CPR protocols offer tremendous potential to save lives, it is remarkable
that survival is still dependent upon early CPR and rapid defibrillation. Indeed, survival
rates fiom cardiac arrest have shown only marginal improvements over the last 30 years,

which further underscores the need for novel therapies and resuscitation strategies.
Second, infarct size needs to be limited. For patients with AM1 who do not succumb to
out-of-hospital arrhythmias and are successfully transported to the hospital, the prognosis
is dependent on the amount of myocardium that is lost as a result of ischemia/reperfusion
injury. There is no question that timely reperfusion (by thrombolysis or percutaneous
transluminal coronary angioplasty [PTCA]) can salvage ischemic myocardium

-

and has,

indeed, become the standard in-hospital treatment for AMI. Although greater benefits can
conceptually be achieved by continued efforts to implement even earlier restoration of
coronary flow, delays in seeking medical attention, together with inherent logistic and
temporal limitations in initiating thrombolysis or PTCA, make it unlikely that additional
and substantive improvements in morbidity and mortality can be achieved by reperfusion
therapy alone.
Limitation of myocardial ischemidreperfusion injury is also of paramount
importance in the setting of global myocardial ischemia associated with coronary artery
bypass graft (CABG) surgery. Despite the considerable progress that has been made to
date, high-risk subsets of patients (i.e., repeat CABG, unstable angina, LV dysfunction,
diabetes, old age, etc.) continue to exhibit post-operative complications, including
prolonged contractile dysfunction (stunning), low-output syndrome, peri-operative
myocardial infarction, and cardiac failure requiring prolonged intensive care. Thus, both
in patients experiencing an AM1 and in those undergoing CABG surgery, there is a
compelling, but still unfulfilled, need to protect the ischemic myocardium.
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In recent studies from Dr. Kukreja's laboratory, it was shown that PDE-5 inhibitors
sildenafil (viagraB) and vardenafil ( ~ e v i t r a ~induce
)
preconditioning-like protective
effects against ischemia-reperfusion injury in adult rabbit hearts. Sildenafil administered
30 minutes (acutely) or 24 hours (delayed) prior to ischemia-reperfusion has previously
been shown to be an effective means for cardioprotection in the rabbit heart (28).
However, the efficacy of these drugs in causing long-term protection following
ischemidreperfusion injury has not been investigated. In this study, we wanted to test if
sildenafil could outlast the second window of protection seen in classical ischemic
preconditioning. Therefore, along with 24-hour delayed protection studies with sildenafil,
we administered sildenafil 48 hrs, 96 hrs, and 7 days prior to undergoing the ischemiareperfusion protocol. We found significant protection at all time points. At 48 hrs, we
observed reduction in infarct size from 34.38% % 1.46 in saline controls to 15.15%

2.01

with sildenafil treatment. On day 7 after administration of sildenafil, the infarct size was
reduced to 16.37%

*

1.94 as compared 37.28%

%

1.39 in saline control (p < 0.05).

Furthermore, we observed a similar reduction in infarct size with vardenafil when
administered 24 hrs or 7 days prior to ischemidreperfusion. This confirms our hypothesis
that PDE-5 inhibitors have a "class effect" in terms of long-term cardioprotection.
Transient decreases in systemic pressures have been reported as acute responses to
both drugs. For example, Ockaili et a1 (28) reported that intravenous administration of
sildenafil caused a rapid decrease in hemodynamics as indicated by the 24.5%, 47.3% and
38.8% decline in systolic, diastolic, and mean arterial pressures, respectively, within 2 min
of receiving the drug. The systemic hemodynamics returned to nearly baseline levels
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5 min after treatment with sildenafil. The effect of orally administered sildenafil citrate on
systemic hemodynamics was milder and slower compared with the intravenous dose of the
drug. The orally administered sildenafil caused a 9.2%, 12.5%, and 10.3% decrease in
systolic, diastolic, and mean arterial pressure, respectively, ,after 30 min of treatment with
the drug. This hypotensive response remained significantly depressed even at 60 min after
oral administration of the drug. No changes in heart rate were observed. However, we did
not see any changes in baseline hemodynamics 24-168 hours after drug administration.
Although L-NAME abolished cardioprotection at all time intervals, suggesting that there
must be some up-regulation of iNOS andlor eNOS protein levels following treatment with
these drugs, this increase may not be enough to elicit a systemic hypotensive response.
Chen et al suggested that hypovolemic hypotension has a preconditioning effect in the
rabbit heart. They found that hypovolemic hypotension preconditioning significantly
improves cardiopulmonary function and increases NO formation and that the protective
benefit associated with hypovolemic hypotension preconditioning of the heart may be
regulated through NO mediated mechanism (6). Therefore, hypotensive preconditioning
could be one of the mechanisms producing a PC-like effect in our long-term studies.
The exact mechanism of long-term protection by PDE-5 inhibition is not filly
understood. However our data suggest that NO generated after treatment with sildenafil or
vardenafil plays an essential role in long-term protection. Treatment with a non-selective
blocker of nitric oxide synthases (L-NAME) abolished the protection conferred by
sildenafil as well as vardenafil. The infarct size was increased to the size similar to saline
controls (Figures 5 and 7). NO has been shown to play a prominent role both in initiating
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and in mediating the cardioprotective response of preconditioning. Several studies from
our laboratory have demonstrated that delayed pharmacological PC is mediated by the
upregulation of iNOS in the myocardium (40, 46, and 47). Bolli and colleagues have
shown that NO is the key trigger as well as a key media$or of PC in rabbit and mouse
hearts (4, 16). In the Langendorff isolated perfused mouse heart model subjected to 20
minutes of global ischemia and 30 minutes of reperfusion, pre-treatment of the animals
with sildenafil reduced myocardial infarct size 24 hours later compared with saline controls
(32).
Sildenafil-induced protection was abolished by a selective iNOS inhibitor, 1400W. In
these studies, sildenafil did not alter pre-ischemic or post-ischemic coronary flow,
indicating that its cardioprotective effect may be independent of its vascular response 24
hours later. RTPCR showed a transient increase in the levels of both eNOS and iNOS,
peaking at 45 minutes (eNOS) and 2 hours (iNOS) after sildenafil treatment and returning
to baseline levels several hours later. The magnitude of increase was much higher for
iNOS mRNA as compared with eNOS mRNA. In addition, cardiac expression of iNOS
and eNOS protein was significantly elevated 24 hours after sildenafil treatment. These
studies suggest that sildenafil induces delayed preconditioning 24 hrs later and that this
response is primarily mediated by NO derived from iNOS.

Similarly in isolated

cardiomyocytes (1 I), sildenafil caused a significant increase in mRNA and protein
expression of iNOS and eNOS (to a lesser extent). Also, sildenafil-induced protection
against necrosis and apoptosis was abolished in myocytes deprived of iNOS, but not in
eNOS gene knockout mice. Interestingly, sildenafil-treated myocytes demonstrated an
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early increase in the Bcl-21Bax ratio following simulated ischemia-reperfusion, which may
have been responsible for the anti-apoptotic effect of sildenafil. The increase of the Bcl21Bax ratio, as well as the anti-apoptotic effects of sildenafil, were inhibited by treatment
with the NOS inhibitor, L-NAME, thus suggesting the role of NO signaling in the
protective effect of the drug against apoptosis. In the present study, the role of NO derived
from nitric oxide synthase is clearly indicated by the ability of L-NAME to block the
protection; however, we have not identified the specific isoform of the enzyme. As
mentioned above, although iNOS is involved in cardioprotection 24 hrs later with
sildenafil, we do not know whether the same isoform of the enzyme is implicated in long
term protection observed at 48-168 hrs following treatment with sildenafil or vardenafil.
Wang et a1 suggested that cardioprotection at 72 hrs after the initial bouts of ischemic
preconditioning was mediated by nNOS and cyclooxygenase-2 (42). Surprisingly, the
iNOS expression was not increased at 72 hours; however, upregulation of nNOS was
evident at both the mRNA as well as protein levels. These changes were accompanied by
an increase in myocardial nitritehitrate. Furthermore, the nNOS-selective inhibitors Npropyl-1-arginine or S-ethyl N-[4-(trifluoromethyl)phenyl] isothiourea completely blocked
the protection of delayed preconditioning at 72 hours, whereas the iNOS-selective inhibitor
S-methylisothiourea had no effect (33). It is possible that a similar shift in the source of
NO occurs following long-term protection with PDE-5 inhibitors. Future studies will
address this important issue.
There are several possibilities by which NO may induce a cardioprotective effect.
Enhanced synthesis of cGMP has been shown to be a requirement for the protection in

delayed-ischemic PC in the rabbit hearts (19). In these studies, the role of cGMP did not
exist during the early (acute) phase of ischemic PC. It was proposed .that NO participates
in PC via two distinct mechanisms; it triggered delayed ischemic PC on acutely via a
cGMP-independent mechanism and yet it mediated delayed PC 24 hrs later via a cGMPdependent mechanism. Furthermore, cGMP may activate PKG (protein kinase G), which
can subsequently open mitochondrial KATPchannels (17). Conceptually, sildenafil plays a
pivotal role in cardioprotection because it inhibits the enzymatic hydrolysis of cGMP and
maintains the tissue accumulation of cGMP, thus leading to the downstream protective
mechanism that involves the PKG-activated mitochondrial-KA~pchannel. In addition, it
was proven that myocardial cGMP content was in fact enhanced following the
pretreatment rats with the cardioprotective dose of sildenafil (1 1). Further studies that
would prove helpfd in this area would be to examine tissue levels of cGMP and NO at the
appropriate time intervals. Quantifying those concentrations in the tissues would allow us
to determine the thresholds these biochemical mediators must reach in order to achieve a
cardioprotective effect with PDE-5 inhibitors in the heart.
The opening of mitochondrial KATPchannels may be one of the important mechanisms
of long-term cardioprotection achieved with PDE-5 inhibitors. Several studies have now
conclusively demonstrated that opening mitoKATPchannels plays an important role in
ischemic as well as pharmacological preconditioning in the heart. In the rabbit studies,
Ockaili et a1 found that both acute and delayed cardioprotective effects were blocked by 5-

HD, suggesting that opening of mitochondrial KATPchannels does in fact play an important
role in the infarct size reduction by sildenafil (28).

Mitochondria are known to play an
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essential role in cell survival by ATP synthesis and maintenance of ca2' homeostasis.
Opening of the mitoKATPchannel partially compensates the membrane potential, which
allows for additional protons to be pumped out, forming an H' electrochemical gradient for
both ATP synthesis and ca2' transport (39, 15). The delayed PC could be through the
signaling cascade leading to the synthesis of iNOS, generation of NO and opening of the
mitoKATPchannels as described previously (27,33, and 43).
In summary, we have shown that a novel class of PDE-5 inhibitors, including
sildenafil

and

vardenafil,

can

reduce

myocardial

infarct

size

following

ischemia/reperfusionup to 7 days following treatment. Our results also suggest that such a
long lasting protective effect of these drugs is mediated by NO generated from nitric oxide
synthase. These studies could be important in terms of harvesting the clinical potential of
phosphodiesterase-5 inhibitors for protection of the heart against ischemiaheperfusion
injury in patients with coronary artery disease.
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